Search | Clinical Trials Finder

Conditions: Kidney Stones
Interventions: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more

Conditions: Recurrent UTIs, Catheter-Related Infections
Interventions: Nissle 1917; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Teen Pregnancy, STD Prevention
Interventions: The IN•clued program; Behavioral
Lead sponsor: Philliber Research & Evaluation; Other
Eligibility: 14 Years and older
Enrollment: 1,401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Accord, New York

Conditions: Focus: Prevent Preterm Delivery, Incidental Short Cervix at Mid-trimester
Interventions: Arabin Pessary; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Invasive Breast Cancer, Ovarian Cancer, Ovarian Cancer Stage 1, Ovarian Cancer Stage II, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Ovarian Cancer Stage IA, Ovarian Cancer Stage IB, Ovarian Cancer Stage IC, Ovarian Cancer Stage 2, Ovarian Cancer Stage 3, Ovarian Cancer Stage IIIb, Ovarian Cancer Stage IIIC, Breast Cancer Stage IIIA, Breast Cancer Invasive, Breast Cancer, Stage IA, Breast Cancer, Stage IB, Breast Cancer Stage IIA, Breast Cancer Stage IIB, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Cancer, Breast, Tumors, Breast, Mammary Cancer, Mammary Carcinoma, Breast Carcinoma, Breast Neoplasm, Malignant Breast Neoplasm, Malignant Tumor of Breast, Cancer of Ovary, Ovary Cancer, Ovary Neoplasm
Interventions: Tart Cherry Juice; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Preterm Birth, Short Cervix
Interventions: Bioteque cup pessary; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Urinary Incontinence
Interventions: BHmApp; Behavioral
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Infantile Hemangioma, Very Low Birth Weight Infants
Interventions: topical 0.5% Timolol maleate, Control (placebo) group; Drug
Lead sponsor: Alice K. Gong; Other
Eligibility: Up to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pre-term Birth
Interventions: Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg, Standard of Care; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Staphylococcus Aureus
Interventions: CA-MRSA Decolonization; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Female only
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome; Dietary Supplement · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 8
States / cities: Cleveland, Ohio

Conditions: Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions: Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Hinsdale, Illinois • Providence, Rhode Island

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: Prevention of Rejection in Kidney Transplant
Interventions: AT-1501; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pregnancy
Interventions: Teen Options to Prevent Pregnancy (T.O.P.P.); Behavioral
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: 10 Years to 19 Years · Female only
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prevention of Pregnancy
Interventions: Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 938 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Preterm Birth
Interventions: Intervention Arm Weekly IP3 text messages, Active Control Arm General pregnancy text messages; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Kidney Injury, Acute
Interventions: Sodium Nitrate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infections, Sexually Transmitted Diseases, Pregnancy
Interventions: HIV, STD, and pregnancy prevention curriculum, Standard sexual education curriculum; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 11 Years to 16 Years
Enrollment: 3,007 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pregnancy, Premature Birth, Prenatal Care, Preterm Delivery, Preterm Birth
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 20,964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polycystic Ovarian Syndrome
Interventions: Flax Seed Oil, Fish Oil, Soybean Oil; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions: Estradiol or Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Gestational Diabetes Mellitus
Interventions: BABI-2 Lifestyle Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Struvite Stones Antibiotic Study

Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children

Evaluation of the Impact of the IN•Clued Curriculum: An LGBTQ Sex ed Program

Arabin Pessary Combine With Vaginal Progesterone Compare With Vaginal Progesterone Alone to Prevent Preterm Delivery in Singleton Pregnancies

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Prevention of Preterm Birth With a Pessary in Singleton Gestations

Evaluation of a New Bladder Health Mobile Application in Pregnancy

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial

A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Evaluation of the Effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) Program

Study of Safety and Efficacy of an Oral Contraceptive

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students

Use of the Perinatal Database and Biologic Tissue Bank at The Perinatology Research Branch (PRB)

Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

Balance After Baby Intervention for Women With Recent Gestational Diabetes